381209-09-2

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Ethylbutyl)cyclohexanecarboxylic acid is used as a building block for the synthesis of pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(2-Ethylbutyl)cyclohexanecarboxylic acid serves as a versatile intermediate for the creation of a wide range of chemical products. Its functional groups and structural features allow for various chemical reactions, enabling the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
1-(2-Ethylbutyl)cyclohexanecarboxylic acid is utilized in medicinal chemistry for the design and development of novel therapeutic agents. Its chemical properties and reactivity make it a promising candidate for the creation of new drugs with potential applications in treating various diseases and medical conditions.

Upstream product

• 3814-34-4 2-ethyl-1-bromobutane 
• 98-89-5 Cyclohexanecarboxylic acid 
• 38225-32-0 lithium isopropylamide 
• 136-01-6 cyclohexanecarboxylic acid Na-salt 
• 24346-54-1 3-(iodomethyl)pentane 
• 158937-75-8 toluene-4-sulfonic acid 2-ethyl-butyl ester 
• 16090-10-1 cyclohexanecarboxylic acid Li-salt 
• 1200437-00-8 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid isopropyl ester 
• 1200437-01-9 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid ethyl ester 
• 1200437-03-1 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid n-propyl ester 
• 1200437-04-2 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid t-butyl ester 
• 1190071-30-7 1-(2-ethylbutyl)cyclohexanecarboxylic acid amide 
• 766-05-2 cyclohexane carbonitrile 

Downstream Products

• 211515-46-7 1-(2-ethyl-butyl)-cyclohexanecarbonyl chloride 
• 211513-15-4 bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide 
• 211513-37-0 dalcetrapib 
• 211513-21-2 Dalcetrapib 

Relevant academic research and scientific papers

METHOD FOR THE PREPARATION OF CYCLOHEXANECARBOXYLIC ACID

A process for the preparation of a compound of formula (I): which are useful as intermediates in the preparation of i.a. pharmaceutically active compounds.

New Process

A process for the preparation of a compound of formula (I): which is useful as an intermediate in the preparation of pharmaceutically active compounds.

NEW PROCESS

A process for the preparation of a compound of formula (I) which are useful as intermediates in the preparation of pharmaceutically active compounds.

New Process

A process for the preparation of a compound of formula (I): which is useful as an intermediate in the preparation of pharmaceutically active compounds.

NOVEL PROCESS

The present invention relates to a process for the preparation of 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid which is useful as an intermediate in the preparation of pharmaceutically active compounds.

PROCESS FOR CYCLOHEXANECARBOXYLIC ACID DERIVATIVES

A process for the preparation of a compound of formula (I): which are useful as intermediates in the preparation of i.a. pharmaceutically active compounds.

PREPARATION FOR A CYCLOHEXANECARBOXYLIC ACID DERIVATIVE AND INTERMEDIATES

A process for the preparation of a compound of formula (Ia): which are useful as intermediates in the preparation of i.a. pharmaceutically active compounds.

Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid

The present invention relates to a process for the preparation of 1-(2-ethyl-butyl)- cyclohexanecarboxylic acid which is useful as an intermediate in the preparation of pharmaceutical active compounds, wherein cyclohexanecarboxylic acid alkali metal salt reacts with an alkylating agent in the presence of a secondary amine and (C1-C6) alkyllithium, (C3-C6) cycloalkyllithium or phenyllithium.

CETP activity inhibitors

The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X1, X2, X3, and X4may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO2—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.

Bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein

A series of bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, S-(2-(acylamino)-phenyl) alkanethioates, and related compounds were synthesized, and their inhibitory effect on cholesteryl ester transfer protein activity in human plasma was evaluated. This study elucidated the structural requirements for inhibitory activity and determined that the optimum compound was S-(2-((1-(2-ethylbutyl)cyclohexane)carbonylamino)phenyl) 2-methylpropanethioate (27) (JTT-705). This compound achieved 50% inhibition of CETP activity in human plasma at a concentration of 9 μM and 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg. It increased the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 or 100 mg/kg once a day for 3 days to male Japanese white rabbits.